Abstract

While the toxicity of PARP inhibitors to cells with defects in homologous recombination (HR) is well established, other synthetic lethal interactions with PARP1/PARP2 disruption are poorly defined. To inform on these mechanisms we conducted a genome-wide screen for genes that are synthetic lethal with PARP1/2 gene disruption and identified C16orf72/HAPSTR1/TAPR1 as a novel modulator of replication-associated R-loops. C16orf72 is critical to facilitate replication fork restart, suppress DNA damage and maintain genome stability in response to replication stress. Importantly, C16orf72 and PARP1/2 function in parallel pathways to suppress DNA:RNA hybrids that accumulate at stalled replication forks. Mechanistically, this is achieved through an interaction of C16orf72 with BRCA1 and the RNA/DNA helicase Senataxin to facilitate their recruitment to RNA:DNA hybrids and confer resistance to PARP inhibitors. Together, this identifies a C16orf72/Senataxin/BRCA1-dependent pathway to suppress replication-associated R-loop accumulation, maintain genome stability and confer resistance to PARP inhibitors.

Here the authors identify that C16orf72 regulates BRCA1/Senataxin to promote replication fork recovery. These proteins act together in a pathway parallel to PARP1 to suppress R-loop accumulation in response to replication stress and confer resistance to PARP inhibitors.

Details

Title
C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption
Author
Sharma, Abhishek Bharadwaj 1   VIAFID ORCID Logo  ; Ramlee, Muhammad Khairul 1 ; Kosmin, Joel 1 ; Higgs, Martin R. 2   VIAFID ORCID Logo  ; Wolstenholme, Amy 1 ; Ronson, George E. 3   VIAFID ORCID Logo  ; Jones, Dylan 4 ; Ebner, Daniel 4   VIAFID ORCID Logo  ; Shamkhi, Noor 1 ; Sims, David 5 ; Wijnhoven, Paul W. G. 6 ; Forment, Josep 6 ; Gibbs-Seymour, Ian 1   VIAFID ORCID Logo  ; Lakin, Nicholas D. 1   VIAFID ORCID Logo 

 University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Birmingham, Institute of Cancer and Genomic Sciences, Edgbaston, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486) 
 University of Oxford, Department of Biochemistry, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Birmingham, Institute of Cancer and Genomic Sciences, Edgbaston, UK (GRID:grid.6572.6) (ISNI:0000 0004 1936 7486) 
 University of Oxford, Target Discovery Institute, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Oxford, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381) 
Pages
5003
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2852214296
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.